Bi-Specific Cancer Treatment Constructs with Different Epitope Binding
Summary
The European Patent Office published patent application EP3484516A1 assigned to Fred Hutchinson Cancer Center on April 8, 2026. The patent covers bi-specific binding domain constructs with different epitope binding properties for treating cancer. The technology falls under IPC classifications A61K 39/395, C07K 16/28, and C12N 15/09, with designated states covering major European markets.
What changed
The EPO granted a new patent (EP3484516A1) to Fred Hutchinson Cancer Center covering bi-specific binding domain constructs with different epitope binding properties for cancer treatment. The invention relates to therapeutic applications in A61P 35/00 (antineoplastic agents) and is classified under antibody and immunoglobulin technologies.\n\nPharmaceutical and biotech entities developing bi-specific antibody constructs or cancer therapeutics should review this patent to assess potential licensing needs or freedom-to-operate implications in European markets, including all designated contracting states.
What to do next
- Monitor for updates
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MULTIPLE BI-SPECIFIC BINDING DOMAIN CONSTRUCTS WITH DIFFERENT EPITOPE BINDING TO TREAT CANCER
Publication EP3484516A1 Kind: A1 Apr 08, 2026
Applicants
Fred Hutchinson Cancer Center
Inventors
MEHLIN, Christopher, CORRENTI, Colin, OLSON, James, WALTER, Roland B., BANDARANAYAKE, Ashok, LASZLO, George S.
IPC Classifications
A61K 39/395 20060101AFI20200206BHEP C07K 16/28 20060101ALI20200206BHEP C12N 15/09 20060101ALI20200206BHEP A61P 35/00 20060101ALI20200206BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.